Abstract
Current cancer treatment paradigms are based on features of the primary tumour and extent of disease. For a group of patients with advanced metastatic disease, this crucial information is missing. Carcinoma of unknown primary (CUP) is a metastatic malignancy in the absence of an identifiable primary tumour. This thesis describes the use of molecular genetic testing to explore whether actionable, oncogenic driver mutations are present in CUP that have potential to better inform treatment decisions. Biologically relevant mutations were detected in the majority of CUP tumours, of which half provided a potentially novel treatment option not generally considered in CUP.
| Original language | English |
|---|---|
| Qualification | Doctor of Philosophy |
| Awarding Institution |
|
| Supervisors/Advisors |
|
| Thesis sponsors | |
| Award date | 25 Oct 2018 |
| DOIs | |
| Publication status | Unpublished - 2018 |
Access to Document
- THESIS - DOCTOR OF PHILOSOPHY - CLYNICK Britt Annaleise - 2018
This work is protected by Copyright. You may print or download ONE copy of this document for the purpose of your own non-commercial research or study. Any other use requires permission from the copyright owner. The Copyright Act requires you to attribute any copyright works you quote or paraphrase.